Trial Profile
A Phase I/II Efficacy and Safety Study of Recombinant Human Hepatocyte Growth Factor (rhHGF) in Patients with Acute Spinal Cord Injury
Status:
Planning
Phase of Trial:
Phase I/II
Latest Information Update: 19 Jun 2014
Price :
$35
*
At a glance
- Drugs Hepatocyte growth factor (Primary)
- Indications Spinal cord injuries
- Focus Adverse reactions; Therapeutic Use
- Sponsors Kringle Pharma
- 19 Jun 2014 New trial record